US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

0.4349

-0.0451-9.40%

Volume:194.55K

Turnover:87.64K

Market Cap:12.38M

PE:-0.15

High:0.4945

Open:0.4888

Low:0.4303

Close:0.4800

Loading ...

Overview Company News Filings

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

BRIEF-Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.d. as CEO and Director

THOMSON REUTERS

Press Release: Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

BRIEF-Calidi Biotherapeutics Announces FDA Clearance Of IND Application For Cld-201 In Solid Tumors

Calidi Biotherapeutics Announces FDA Clearance of Ind Application for Cld-201 in Solid Tumors

THOMSON REUTERS

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Press Release: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Q4 EPS (0.27) Down From ($0.23) YoY

Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Inc -Pricing of $3.9 Mln Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

BRIEF-Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial With Cld-101 Virotherapy in Patients With Recurrent High-Grade Glioma

THOMSON REUTERS

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLDI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLDI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.4349,"timestamp":1746561600000,"preClose":0.48,"halted":0,"volume":194545,"delay":0,"floatShares":25741600,"shares":28467600,"eps":-2.97489,"marketStatus":"Pre-Mkt","change":-0.0451,"latestTime":"05-07 08:21:35 EDT","open":0.4888,"high":0.4945,"low":0.4303,"amount":87641.6470475,"amplitude":0.13375,"askPrice":0.4884,"askSize":100,"bidPrice":0.4349,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.97489,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746624600000},"marketStatusCode":1,"adr":0,"exchange":"AMEX","adjPreClose":0.4349,"postHourTrading":{"tag":"盘后","latestPrice":0.4321,"preClose":0.4349,"latestTime":"19:53 EDT","volume":16737,"amount":7224.3713,"timestamp":1746575598635},"volumeRatio":1.3715625643637295},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","floatShares":25741600,"roa":"-112.47%","roe":"--","lyrEps":-2.97489,"volumeRatio":1.3715625643637295,"shares":28467600,"dividePrice":0,"high":0.4945,"amplitude":0.13375,"preClose":0.48,"low":0.4303,"week52Low":0.35,"pbRate":"8.07","week52High":4.9,"institutionHeld":0,"latestPrice":0.4349,"eps":-2.97489,"divideRate":0,"volume":194545,"delay":0,"ttmEps":-2.97489,"open":0.4888,"prevYearClose":1.15,"prevWeekClose":0.4981,"prevMonthClose":0.4825,"prevQuarterClose":0.5662,"fiveDayClose":0.4939,"twentyDayClose":0.4961,"sixtyDayClose":1.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530400475","title":"Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530400475","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530400475?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist  as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research  Annual Meeting on April 27, 2025, in Chicago, IL.“IL15 superagonist is a potent cytokine capable of generating robust and durable immune responses against tumors but can induce severe toxicity when administered systemically” said Antonio F. Santidrian, PhD, Chief Scientific Officer at Calidi. “By using tumor-targeted virotherapies systemically delivered to express therapeutic proteins like IL-15 superagonist directly into the tumor microenvironment, we believe we can effectively boost immune response against the tumors precisely where it is needed while minimizing systemic toxicity”.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-announces-il15-superagonist-120000819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2529750259","title":"BRIEF-Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529750259","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529750259?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:09","pubTimestamp":1745410183,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And DirectorApril 23 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA14FPTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2529410504","title":"Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.d. as CEO and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529410504","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529410504?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA14FPTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2529550417","title":"Press Release: Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529550417","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529550417?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director. SAN DIEGO, April 23, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer , Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi , effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.\"We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepares for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors,\" said Mr. James Schoeneck, Chairman of the Board. \"On behalf of the Board, we would like to thank Allan for his visionary leadership ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2529304850","title":"Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2529304850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529304850?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:00","pubTimestamp":1745323200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 22, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature Calidi’s newly appointed Chief Medical Officer, Consultant and Advisor, Guy Travis Clifton, MD, who will share insight into the company’s groundbreaking stem cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Dr. Clifton will be joined by Calidi’s CFO Andrew Jackson.Highlights of the webinar will also include overviews of Calidi’s other lead programs, such as CLD-400 or RTNova, a systemic platform targeting metastatic and lung cancer and CLD-101, designed to treat high-grade gliomas. A live Q&A session with the leadership team will follow the presentation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-calidi-biotherapeutics-exclusive-live-120000816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2528571725","title":"BRIEF-Calidi Biotherapeutics Announces FDA Clearance Of IND Application For Cld-201 In Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2528571725","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528571725?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:07","pubTimestamp":1744895257,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces FDA Clearance Of IND Application For Cld-201 In Solid TumorsApril 17 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2528716121","title":"Calidi Biotherapeutics Announces FDA Clearance of Ind Application for Cld-201 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528716121?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2528999714","title":"Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2528999714","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528999714?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 17, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma.Calidi Biotherapeutics  is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolyti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-announces-fda-clearance-120000209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2524270972","title":"Press Release: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524270972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524270972?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:30","pubTimestamp":1743453000,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement. The combined offering price for each share of common stock  and accompanying warrants was $0.65 . The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance, and will not expire until fully exercised. The Series G warrants have an exercise price of $0.6954 per share, are exercisable six  months from the date of issuance and will expire seven and one-half years following the initial exercise date. The securities issued in this transaction do not contain any variable or priced based resets.The series G warrants described above were offered in a private placement under Section 4","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2524723809","title":"Calidi Biotherapeutics Q4 EPS (0.27) Down From ($0.23) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524723809","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524723809?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:18","pubTimestamp":1743452322,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Q4 EPS (0.27) Down From ($0.23) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44571395/calidi-biotherapeutics-q4-eps-0-27-down-from-0-23-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI"],"gpt_icon":0},{"id":"2524744149","title":"Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524744149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524744149?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:10","pubTimestamp":1743451800,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights. -- Announced demonstrated ability to deliver transient gene therapy. -- Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to. -- Commencement of recruitment for Phase 1 trial in patients with newly. SAN DIEGO, March 31, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights.\"Calidi continues to make great progress on all three of our platforms; our systemic asset CLD-400 proved it can deliver a gene therapy payload to targeted tumors, we filed an IND for our solid tumor asset CLD-201, and our CLD-101 program treating high-grade glioma is advancing in two Phase 1 trials,\" said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. \"We","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2522825574","title":"Calidi Biotherapeutics Inc -Pricing of $3.9 Mln Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2522825574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522825574?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:04","pubTimestamp":1743167079,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2522024571","title":"Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2522024571","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522024571?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:00","pubTimestamp":1743166800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 28, 2025  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies,today announced that it has entered into a definitive securities purchase agreement with a single institutional investor for the purchase and sale of 3,325,000 shares of the Company’s common stock at a per share purchase price of $0.65, and at the election of the investor, in lieu of the common stock, pre-funded warrants to purchase up to 2,728,000 shares of Common Stock at a price of $0.649 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant, in a registered direct offering.In addition, in aconcurrent private placement, the Company will issue to the investors series G warrants to purchase up to 6,053,000 shares of common stock. The series G warrants have an exercise price of $0.6954 per share, will be exercisable six mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-announces-pricing-3-130000494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2522487444","title":"BRIEF-Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522487444","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522487444?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:06","pubTimestamp":1742990799,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade GliomaMarch 26 (Reuters) - Calidi Biotherapeutic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7F6CWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2522710348","title":"Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial With Cld-101 Virotherapy in Patients With Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522710348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522710348?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7F6CWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2522805991","title":"Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805991","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805991?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"SAN DIEGO and LOS ANGELES, March 26, 2025  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, and City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, are pleased to jointly announce progress from a phase 1 clinical trial utilizing Calidi’s CLD-101 investigational agent  that is administered intracerebrally. This trial is the first to evaluate the safety and therapeutic potential of a multiple-dose regimen of this novel virotherapy for recurrent high-grade glioma - among the most aggressive and deadly forms of brain cancer.Conducted by City of Hope, which has a National Cancer Institute-designated Comprehensive Cancer Center known for its pioneering research, this physician-sponsored phase 1 trial is assessing the safety and feasibility of delivering up to four weekly intracerebral doses of CLD-101. To date, 14 participants have been tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-city-hope-phase-120000169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HOPE","CHCO","BK4211","BK4139","CLDI"],"gpt_icon":0},{"id":"2519801176","title":"Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2519801176","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519801176?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:00","pubTimestamp":1741957200,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc.  and Calidi Biotherapeutics, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-calidi-biotherapeutics-interviews-130000894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TV","BK4144","ET","BK4585","BK4555","NXLIW","BK4187","CLDI","BK4588","BK4590","BK4099","BK4581","TM","BK4604","AIRI","BK4561","03160","NXL","BK4100"],"gpt_icon":0},{"id":"2518893766","title":"Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2518893766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518893766?lang=en_us&edition=fundamental","pubTime":"2025-03-11 14:30","pubTimestamp":1741674605,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 11th, 2025, FinanceWire Calidi Biotherapeutics (NYSE American: CLDI) announced positive preclinical results for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/calidi-biotherapeutics-nyse-american-cldi-reports-promising-preclinical-results-for-rtnova-virotherapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/calidi-biotherapeutics-nyse-american-cldi-reports-promising-preclinical-results-for-rtnova-virotherapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","AFG","CLDI","BK4139","BK4117","NYSE"],"gpt_icon":0},{"id":"2518228428","title":"Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228428","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228428?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 10, 2025  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered transient gene therapy payloads to targeted tumors. Additionally, Calidi's tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.The RTNova platform addresses the challenges of treating advanced-stage metastatic cancers, including lung cancer, when intratumoral administration is not feasible. Calidi designed an innovative vaccinia virus strain enveloped with a human cell membrane , providing protection in the bloodstream while targeting distant tumors. Once inside the tumor, virotherapies are designed to selectively replicate and destroy tumor cells. This process induces an immune response, training the immune system to recognize and target future cancer cells. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-announces-demonstrated-ability-120000806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ABIL","CLDI"],"gpt_icon":0},{"id":"2514189327","title":"Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2514189327","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514189327?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and OS Therapies Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-os-therapies-interviews-140000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4604","BK4080","BK4581","ET","BK4555","BK4097","ADC","BK4139","TV","BK4585","OSTX","BK4187","BK4231","BK4590","AIRI","BK4561","OS","BK4099","BK4100","03160","CLDI","TM","BK4144"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-07-15","symbol":"CLDI","defaultRemindTime":1721050200000,"type":"split","dateTimestamp":1721016000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1719547200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLDI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLDI","date":"2025-05-06","current":-0.787331,"percent":0.425134,"low":-6.02184,"twenty":-1.558504,"median":-0.713725,"eighty":-0.410381,"high":-0.237196,"avg":-1.022484,"sd":0.845149,"marketCap":17433878},"quantilePoints":[{"date":"2023-09-29","current":-3.638343,"twenty":-5.308141,"median":-4.713391,"eighty":-4.212002,"marketCap":116696199},{"date":"2023-10-06","current":-3.412521,"twenty":-4.832341,"median":-4.127586,"eighty":-3.638343,"marketCap":109453210},{"date":"2023-10-13","current":-3.406945,"twenty":-4.642021,"median":-3.525432,"eighty":-3.367913,"marketCap":109274365},{"date":"2023-10-20","current":-3.122569,"twenty":-4.220957,"median":-3.406945,"eighty":-3.283158,"marketCap":100153264},{"date":"2023-10-27","current":-2.788008,"twenty":-3.847474,"median":-3.379065,"eighty":-3.220707,"marketCap":89422557},{"date":"2023-11-03","current":-1.828933,"twenty":-3.642821,"median":-3.289849,"eighty":-2.58281,"marketCap":58661197},{"date":"2023-11-10","current":-2.263862,"twenty":-3.457685,"median":-3.122569,"eighty":-2.272784,"marketCap":72611116},{"date":"2023-11-17","current":-2.442295,"twenty":-3.40806,"median":-2.704368,"eighty":-2.257171,"marketCap":78334160},{"date":"2023-11-24","current":-2.219166,"twenty":-3.390217,"median":-2.436719,"eighty":-2.230406,"marketCap":63785485},{"date":"2023-12-01","current":-2.589027,"twenty":-3.358991,"median":-2.397687,"eighty":-2.219166,"marketCap":74416400},{"date":"2023-12-08","current":-2.860258,"twenty":-3.332227,"median":-2.436719,"eighty":-2.22591,"marketCap":82212403},{"date":"2023-12-15","current":-2.835601,"twenty":-3.283158,"median":-2.620727,"eighty":-2.230406,"marketCap":81503676},{"date":"2023-12-22","current":-2.220879,"twenty":-3.249702,"median":-2.454969,"eighty":-2.220879,"marketCap":63834719},{"date":"2023-12-29","current":-1.739688,"twenty":-3.220707,"median":-2.431143,"eighty":-2.219509,"marketCap":50003863},{"date":"2024-01-05","current":-1.752027,"twenty":-3.147103,"median":-2.407056,"eighty":-2.219166,"marketCap":50358500},{"date":"2024-01-12","current":-1.628644,"twenty":-3.080391,"median":-2.314664,"eighty":-2.158893,"marketCap":46812127},{"date":"2024-01-19","current":-1.492924,"twenty":-2.974346,"median":-2.305467,"eighty":-1.939518,"marketCap":42911116},{"date":"2024-01-26","current":-1.204827,"twenty":-2.880427,"median":-2.269438,"eighty":-1.766833,"marketCap":34630335},{"date":"2024-02-02","current":-0.987855,"twenty":-2.845464,"median":-2.230406,"eighty":-1.702674,"marketCap":28393922},{"date":"2024-02-09","current":-0.730889,"twenty":-2.828204,"median":-2.220879,"eighty":-1.569421,"marketCap":21007953},{"date":"2024-02-16","current":-0.617286,"twenty":-2.802114,"median":-2.220879,"eighty":-1.222224,"marketCap":17742652},{"date":"2024-02-23","current":-1.223953,"twenty":-2.75773,"median":-2.219166,"eighty":-1.201248,"marketCap":35180069},{"date":"2024-03-01","current":-0.737187,"twenty":-2.712314,"median":-2.219166,"eighty":-1.144986,"marketCap":21188964},{"date":"2024-03-08","current":-0.857685,"twenty":-2.707382,"median":-2.174646,"eighty":-1.007118,"marketCap":24652427},{"date":"2024-03-15","current":-0.752972,"twenty":-2.675328,"median":-2.00496,"eighty":-0.959654,"marketCap":21642662},{"date":"2024-03-22","current":-0.731293,"twenty":-2.63341,"median":-1.828933,"eighty":-0.834401,"marketCap":21365466},{"date":"2024-03-28","current":-0.690544,"twenty":-2.624956,"median":-1.776703,"eighty":-0.788933,"marketCap":20174941},{"date":"2024-04-05","current":-0.515506,"twenty":-2.614387,"median":-1.733519,"eighty":-0.77599,"marketCap":15061018},{"date":"2024-04-12","current":-0.778003,"twenty":-2.56475,"median":-1.702674,"eighty":-0.753894,"marketCap":22730126},{"date":"2024-04-19","current":-0.277851,"twenty":-2.462573,"median":-1.585461,"eighty":-0.73922,"marketCap":8117685},{"date":"2024-04-26","current":-0.277851,"twenty":-2.440065,"median":-1.494131,"eighty":-0.729834,"marketCap":8117685},{"date":"2024-05-03","current":-0.33683,"twenty":-2.428199,"median":-1.326872,"eighty":-0.713833,"marketCap":9840816},{"date":"2024-05-10","current":-0.388779,"twenty":-2.412677,"median":-1.223953,"eighty":-0.694949,"marketCap":11358553},{"date":"2024-05-17","current":-0.395215,"twenty":-2.384304,"median":-1.201804,"eighty":-0.67322,"marketCap":11848146},{"date":"2024-05-24","current":-0.389826,"twenty":-2.327552,"median":-1.110439,"eighty":-0.59822,"marketCap":11686581},{"date":"2024-05-31","current":-0.489936,"twenty":-2.314664,"median":-1.049596,"eighty":-0.481812,"marketCap":14687785},{"date":"2024-06-07","current":-0.316825,"twenty":-2.30847,"median":-0.987793,"eighty":-0.405177,"marketCap":9498101},{"date":"2024-06-14","current":-0.471065,"twenty":-2.306068,"median":-0.973968,"eighty":-0.411637,"marketCap":14122049},{"date":"2024-06-21","current":-0.417535,"twenty":-2.287195,"median":-0.942383,"eighty":-0.415168,"marketCap":12517271},{"date":"2024-06-28","current":-0.442801,"twenty":-2.275014,"median":-0.891807,"eighty":-0.416445,"marketCap":13274726},{"date":"2024-07-05","current":-0.415179,"twenty":-2.275014,"median":-0.841776,"eighty":-0.414794,"marketCap":12446661},{"date":"2024-07-12","current":-0.324606,"twenty":-2.266092,"median":-0.802632,"eighty":-0.404243,"marketCap":9731376},{"date":"2024-07-15","current":-0.338952,"twenty":-2.263862,"median":-0.798467,"eighty":-0.400509,"marketCap":10161455},{"date":"2024-08-02","current":-0.357581,"twenty":-2.257171,"median":-0.794302,"eighty":-0.396487,"marketCap":10719918},{"date":"2024-08-09","current":-0.398883,"twenty":-2.230406,"median":-0.779498,"eighty":-0.390904,"marketCap":11958114},{"date":"2024-08-16","current":-0.480755,"twenty":-2.230406,"median":-0.778003,"eighty":-0.392451,"marketCap":11175142},{"date":"2024-08-23","current":-0.500804,"twenty":-2.228501,"median":-0.759804,"eighty":-0.395268,"marketCap":11641180},{"date":"2024-08-30","current":-0.382558,"twenty":-2.220879,"median":-0.750634,"eighty":-0.391354,"marketCap":8892568},{"date":"2024-09-06","current":-0.39647,"twenty":-2.220879,"median":-0.737187,"eighty":-0.391253,"marketCap":9215934},{"date":"2024-09-13","current":-0.403425,"twenty":-2.220879,"median":-0.730361,"eighty":-0.39176,"marketCap":9377617},{"date":"2024-09-20","current":-0.384297,"twenty":-2.220879,"median":-0.726938,"eighty":-0.391253,"marketCap":8932989},{"date":"2024-09-27","current":-0.420814,"twenty":-2.219166,"median":-0.713995,"eighty":-0.389826,"marketCap":9781825},{"date":"2024-10-04","current":-0.375603,"twenty":-2.219166,"median":-0.705506,"eighty":-0.388779,"marketCap":8730885},{"date":"2024-10-11","current":-0.484689,"twenty":-2.219166,"median":-0.691943,"eighty":-0.386036,"marketCap":11266594},{"date":"2024-10-18","current":-0.559329,"twenty":-2.219166,"median":-0.675446,"eighty":-0.386036,"marketCap":13001597},{"date":"2024-10-25","current":-0.336452,"twenty":-2.219166,"median":-0.638834,"eighty":-0.386036,"marketCap":7820838},{"date":"2024-10-31","current":-0.530552,"twenty":-2.18355,"median":-0.601504,"eighty":-0.386036,"marketCap":12332679},{"date":"2024-11-08","current":-0.740861,"twenty":-2.174646,"median":-0.630927,"eighty":-0.38823,"marketCap":17221309},{"date":"2024-11-15","current":-0.849939,"twenty":-2.111632,"median":-0.664773,"eighty":-0.389367,"marketCap":22332149},{"date":"2024-11-22","current":-1.580558,"twenty":-2.067561,"median":-0.675446,"eighty":-0.389764,"marketCap":41529165},{"date":"2024-11-29","current":-1.558504,"twenty":-1.993856,"median":-0.690544,"eighty":-0.390682,"marketCap":40949688},{"date":"2024-12-06","current":-1.477638,"twenty":-1.934558,"median":-0.69736,"eighty":-0.391557,"marketCap":38824940},{"date":"2024-12-13","current":-1.374718,"twenty":-1.867215,"median":-0.712804,"eighty":-0.392499,"marketCap":36120716},{"date":"2024-12-20","current":-1.065958,"twenty":-1.812401,"median":-0.717637,"eighty":-0.394326,"marketCap":28008041},{"date":"2024-12-27","current":-1.088012,"twenty":-1.791509,"median":-0.728386,"eighty":-0.395322,"marketCap":28587518},{"date":"2025-01-03","current":-0.867469,"twenty":-1.774231,"median":-0.730361,"eighty":-0.39568,"marketCap":22792751},{"date":"2025-01-10","current":-0.992443,"twenty":-1.764344,"median":-0.73424,"eighty":-0.39647,"marketCap":26076452},{"date":"2025-01-17","current":-0.658321,"twenty":-1.752027,"median":-0.729834,"eighty":-0.39647,"marketCap":17297380},{"date":"2025-01-24","current":-0.559444,"twenty":-1.742156,"median":-0.726938,"eighty":-0.39647,"marketCap":14699393},{"date":"2025-01-31","current":-0.459906,"twenty":-1.730007,"median":-0.713995,"eighty":-0.3984,"marketCap":12084021},{"date":"2025-02-07","current":-1.088012,"twenty":-1.727397,"median":-0.721011,"eighty":-0.399734,"marketCap":28587518},{"date":"2025-02-14","current":-0.992443,"twenty":-1.707609,"median":-0.729834,"eighty":-0.399947,"marketCap":26076452},{"date":"2025-02-21","current":-0.926281,"twenty":-1.702674,"median":-0.731091,"eighty":-0.399947,"marketCap":24338022},{"date":"2025-02-28","current":-0.612521,"twenty":-1.691156,"median":-0.729834,"eighty":-0.399947,"marketCap":16094000},{"date":"2025-03-07","current":-0.624578,"twenty":-1.650578,"median":-0.723974,"eighty":-0.400284,"marketCap":16410780},{"date":"2025-03-14","current":-0.571942,"twenty":-1.617436,"median":-0.713824,"eighty":-0.401215,"marketCap":15027763},{"date":"2025-03-21","current":-0.580763,"twenty":-1.605553,"median":-0.709155,"eighty":-0.402729,"marketCap":15259553},{"date":"2025-03-28","current":-0.511219,"twenty":-1.596023,"median":-0.693342,"eighty":-0.403425,"marketCap":13432270},{"date":"2025-04-04","current":-0.459715,"twenty":-1.584987,"median":-0.688902,"eighty":-0.403425,"marketCap":10179474},{"date":"2025-04-11","current":-0.669232,"twenty":-1.579798,"median":-0.693063,"eighty":-0.404476,"marketCap":14818796},{"date":"2025-04-17","current":-0.762727,"twenty":-1.576858,"median":-0.698757,"eighty":-0.405589,"marketCap":16889069},{"date":"2025-04-25","current":-0.815708,"twenty":-1.567326,"median":-0.703771,"eighty":-0.407877,"marketCap":18062224},{"date":"2025-05-02","current":-0.791432,"twenty":-1.558504,"median":-0.712804,"eighty":-0.410381,"marketCap":17524679},{"date":"2025-05-06","current":-0.787331,"twenty":-1.558504,"median":-0.713725,"eighty":-0.410381,"marketCap":17433878}],"updateTime":1746620495969}}}